Search Results - "DEAN, Reginald L"

Refine Results
  1. 1

    Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat by Smith, Karen L., Cunningham, Jacobi I., Eyerman, David J., Dean, Reginald L., Deaver, Daniel R., Sanchez, Connie

    Published in Neuropharmacology (01-03-2019)
    “…Approximately two-thirds of major depressive disorder (MDD) patients do not respond adequately to current therapies. BUP/SAM (ALKS 5461), a combination of…”
    Get full text
    Journal Article
  2. 2

    Pharmaceutical treatment for cognitive deficits in Alzheimer’s disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps by Bartus, Raymond T., Dean, Reginald L.

    Published in Psychopharmacology (2009)
    “…Rationale Over 30 years ago, we began to develop a nonhuman primate model to study cognitive deficits of age-related neurodegenerative diseases and their…”
    Get full text
    Journal Article
  3. 3

    The Role of Leukocytes Following Cerebral Ischemia: Pathogenic Variable or Bystander Reaction to Emerging Infarct? by Emerich, Dwaine F., Dean, Reginald L., Bartus, Raymond T.

    Published in Experimental Neurology (01-01-2002)
    “…Data accumulated over the last 10 years have led to the popular hypothesis that neutrophils and other inflammatory cells play a prominent role in the…”
    Get full text
    Book Review Journal Article
  4. 4

    Opioid receptor modulation of neural circuits in depression: What can be learned from preclinical data? by Puryear, Corey B., Brooks, Julie, Tan, Laura, Smith, Karen, Li, Yan, Cunningham, Jacobi, Todtenkopf, Mark S., Dean, Reginald L., Sanchez, Connie

    Published in Neuroscience and biobehavioral reviews (01-01-2020)
    “…•The opioid system has a key role in modulating neural systems dysregulated in MDD.•Opioids have effects on reward processing and emotional regulation in…”
    Get full text
    Journal Article
  5. 5

    Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates by Cunningham, Jacobi I, Eyerman, David J, Todtenkopf, Mark S, Dean, Reginald L, Deaver, Daniel R, Sanchez, Connie, Namchuk, Mark

    Published in Journal of psychopharmacology (Oxford) (01-10-2019)
    “…Background: Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of…”
    Get full text
    Journal Article
  6. 6

    Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats by Smith, Sharon L, Dean, Reginald L, Todtenkopf, Mark S, Heal, David J

    Published in Journal of psychopharmacology (Oxford) (01-03-2019)
    “…Background: Samidorphan is a novel μ-opioid antagonist with low intrinsic activity at κ- and δ-opioid receptors. Aims: Because samidorphan is central nervous…”
    Get full text
    Journal Article
  7. 7

    Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model by Callaghan, Charlotte K., Rouine, Jennifer, Dean, Reginald L., Knapp, Brian I., Bidlack, Jean M., Deaver, Daniel R., O'Mara, Shane M.

    Published in Brain, behavior, and immunity (01-01-2018)
    “…•IFN-α treatment induced depressive-like and cognitive deficits in the rat.•IFN-α increased IL-6, IL-1β and corticosterone, and decreased neurogenesis and…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Prodrugs of Pioglitazone for Extended-Release (XR) Injectable Formulations by Sanrame, Carlos N, Remenar, Julius F, Blumberg, Laura C, Waters, Julie, Dean, Reginald L, Dong, Nan, Kriksciukaite, Kristi, Cao, Peixin, Almarsson, Örn

    Published in Molecular pharmaceutics (06-10-2014)
    “…N-Acyloxymethyl derivatives of pioglitazone (PIO) have been prepared and characterized as model candidates for extended-release injectable formulations. All…”
    Get full text
    Journal Article
  10. 10

    The Cholinergic Hypothesis of Geriatric Memory Dysfunction by Bartus, Raymond T., Dean, Reginald L., Beer, Bernard, Lippa, Arnold S.

    “…Biochemical, electrophysiological, and pharmacological evidence supporting a role for cholinergic dysfunction in age-related memory disturbances is critically…”
    Get full text
    Journal Article
  11. 11

    Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats by Dean, Reginald L., Eyerman, David, Todtenkopf, Mark S., Turncliff, Ryan Z., Bidlack, Jean M., Deaver, Daniel R.

    Published in Pharmacology, biochemistry and behavior (01-01-2012)
    “…Naltrexone is a μ-opioid receptor antagonist that has been extensively studied for its ability to block the rewarding effects of ethanol. Opioid receptors are…”
    Get full text
    Journal Article
  12. 12

    Effects of Extended-Release Injectable Naltrexone on Self-Injurious Behavior in Rhesus Macaques (Macaca mulatta) by Kempf, Doty J, Baker, Kate C, Gilbert, Margaret H, Blanchard, James L, Dean, Reginald L, Deaver, Daniel R, Bohm, Rudolf P

    Published in Comparative medicine (01-06-2012)
    “…Self-injurious behavior (SIB) is a spontaneous behavior that threatens the health and wellbeing of multiple species. In humans, the opioid antagonist…”
    Get full text
    Journal Article
  13. 13

    Naltrexone decreases D-amphetamine and ethanol self-administration in rhesus monkeys by Jimenez-Gomez, Corina, Winger, Gail, Dean, Reginald L, Deaver, Daniel R, Woods, James H

    Published in Behavioural pharmacology (01-02-2011)
    “…Amphetamines are the second most highly abused illicit drugs worldwide, yet there is no pharmacological treatment for amphetamine abuse and dependence…”
    Get full text
    Journal Article
  14. 14

    Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone by Dean, Reginald L., Todtenkopf, Mark S., Deaver, Daniel R., Arastu, Mahin F., Dong, Nan, Reitano, Krystal, O'Driscoll, Kevin, Kriksciukaite, Kristina, Gastfriend, David R.

    Published in Pharmacology, biochemistry and behavior (01-06-2008)
    “…A monthly extended-release formulation of the opioid antagonist naltrexone (XR-NTX) is approved for treatment of alcohol dependence. There is little research…”
    Get full text
    Journal Article
  15. 15

    Vivitrex , an Injectable, Extended-Release Formulation of Naltrexone, Provides Pharmacokinetic and Pharmacodynamic Evidence of Efficacy for 1 Month in Rats by Bartus, Raymond T, Emerich, Dwaine F, Hotz, Joyce, Blaustein, Marc, Dean, Reginald L, Perdomo, Brigido, Basile, Anthony S

    Published in Neuropsychopharmacology (01-11-2003)
    “…While oral naltrexone is effective in treating alcohol and opiate dependencies, poor patient adherence and widely fluctuating plasma levels limit its efficacy…”
    Get full text
    Journal Article
  16. 16
  17. 17

    The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier from concept to clinical evaluation by EMERICH, Dwaine F, DEAN, Reginald L, OSBORN, Chester, BARTUS, Raymond T

    Published in Clinical pharmacokinetics (2001)
    “…Labradimil (Cereport; also formerly referred to as RMP-7) is a 9-amino-acid peptide designed for selectivity for the bradykinin B2 receptor and a longer plasma…”
    Get full text
    Journal Article
  18. 18

    Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats by Todtenkopf, Mark S, O'Neill, Krystal S, Kriksciukaite, Kristina, Turncliff, Ryan Z, Dean, Reginald L, Ostrovsky-Day, Irina, Deaver, Daniel R

    Published in Addiction biology (01-10-2009)
    “…Opioid receptor antagonism has been shown to attenuate behavioral and neurochemical effects of amphetamine in humans and rodents. The effects of acute (oral or…”
    Get full text
    Journal Article
  19. 19

    Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage by Bartus, R T, Baker, K L, Heiser, A D, Sawyer, S D, Dean, R L, Elliott, P J, Straub, J A

    “…Experiments were conducted to determine whether a potent, reversible calpain inhibitor could reduce the cortical ischemic brain damage associated with focal…”
    Get more information
    Journal Article
  20. 20

    Time-related neuronal changes following middle cerebral artery occlusion: implications for therapeutic intervention and the role of calpain by Bartus, R T, Dean, R L, Cavanaugh, K, Eveleth, D, Carriero, D L, Lynch, G

    “…Changes in neocortex and striatum were characterized over time following focal ischemia to the brain. Rats were subjected to permanent middle cerebral artery…”
    Get more information
    Journal Article